Big news: The JNJ vaccine results of 44,000 Phase 3 trial, a single dose. Overall 66% efficacy, with the contrast of 72% in US but 57% in South Africa, confirming immune escape/resistance of B.1.351 variant seen by Novavax

This news is certainly welcome, clearly fulfills FDA threshold and adds to the vaccine tool chest. It is a clear drop down from the 2-dose mRNA efficacy
https://www.statnews.com/2021/01/29/jj-one-dose-covid-vaccine-is-66-effective-a-weapon-but-not-a-knockout-punch/ @matthewherper @statnews

I have to revise the #SARSCoV2 Variant table with latest information from past 12 hours

The JNJ @JanssenUS trial had 468 endpoints, the most infection events of any of the trials to date for assessment of efficacy, vaccine 85% effective vs severe events, and diversity of participants: 45% Latino, 19% Black, 9% Native American

So we now have 3 different types of vaccines with efficacy against #SARSCoV2: mRNA, protein, and adenovirus vectors. We've also seen failure of a major vaccine program @Merck. All of this in less than a year represents remarkable progress vs a very formidable challenge.